Streptococcus pneumoniae News and Research

RSS

Streptococcus pneumoniae, or Pneumococcus, is a very common bacterial infection in both industrialized and developing countries. In particular, young children and the elderly represent high-risk populations of developing pneumococcal infections. According to the WHO, the bacterium kills up to one million children under the age of five years each year worldwide. It accounts for many Bacterial Meningitis cases in adults and it is the most common cause of Bacteraemia, Pneumonia, Meningitis and Otitis media in young children.

New method can screen for bacterial genes that are expressed during meningitis

Bacterial meningitis is an infection of the meninges, the protective membrane that covers the spinal cord and brain. Children, elderly patients and immunocompromised patients are at a higher risk for the development of severe bacterial meningitis. Recently, researchers at the University of Adelaide in Australia sought to identify new vaccine targets in Streptococcus pneumoniae, which is the most common cause of bacterial meningitis in the world.

25 May 2012

CLYD gene serves as crucial negative regulator in pulmonary fibrosis

An international team of researchers led by Georgia State University scientists have found a key component in the pathological process of pulmonary fibrosis, a fatal disease for which there is currently no cure.

11 Apr 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

New insight into causes of childhood pneumonia

The scientific journal Clinical Infectious Diseases has released its March Special Supplement focusing entirely on the research design of and pilot data from the Pneumonia Etiology Research for Child Health (PERCH) Project, which seeks to identify the causes of pneumonia among the world's most vulnerable populations.

12 Mar 2012

Epidemic bacteria can damage mucins to enter and infect a body part

Boston, MA- Scientists from the Schepens Eye Research Institute, a subsidiary of Mass. Eye and Ear and affiliate of Harvard Medical School, have found for the first time that a bacterial pathogen can literally mow down protective molecules, known as mucins, on mucus membranes to enter and infect a part of the body.

12 Mar 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

Study investigates how bacteria change their disguise to evade vaccines

Genetics has provided surprising insights into why vaccines used in both the UK and US to combat serious childhood infections can eventually fail. The study, published today in Nature Genetics, which investigates how bacteria change their disguise to evade the vaccines, has implications for how future vaccines can be made more effective.

30 Jan 2012

Pfizer’s Prevenar 13 gets US approval for adults

Health authorities of United States have approved the expansion of Pfizer Inc's Prevnar vaccine for use in adults 50 and older to fight pneumonia, meningitis and other diseases cause by pneumococcus bacteria. The vaccine, which had been approved for children in the United States, is already one of Pfizer's biggest brands and an expanded population of adults could generate more than $1.5 billion in annual sales.

2 Jan 2012

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

Prevnar 13, a pneumococcal 13-valent conjugate vaccine, was approved today by the U.S. Food and Drug Administration for people ages 50 years and older to prevent pneumonia and invasive disease caused by the bacterium, Streptococcus pneumoniae.

31 Dec 2011

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.

31 Dec 2011

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.

17 Dec 2011

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine, for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.

27 Oct 2011

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Pfizer Inc. announced today that additional data from several clinical studies of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America, which is being held Oct. 20-23, 2011, in Boston, Mass.

22 Oct 2011

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Furiex Pharmaceuticals, Inc. today announced recent and upcoming publications and presentations about the novel investigational antibacterial drug JNJ-Q2.

12 Oct 2011

Researchers discover how a novel type of antibody works against pneumococcal bacteria

Researchers at Albert Einstein College of Medicine of Yeshiva University have discovered how a novel type of antibody works against pneumococcal bacteria.

23 Sep 2011

High risk of serious complications or death in children with SP-HUS

Hemolytic uremic syndrome (HUS) caused by infection with pneumococcal bacteria leads to severe illness—with a high rate of irreversible kidney damage—in infants and young children, reports a study in the September issue of The Pediatric Infectious Disease Journal.

30 Aug 2011

Isconova expands Matrix M collaboration with Genocea to treat infectious diseases

Isconova AB, a leading international vaccine adjuvant company and Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell‐based vaccines, today announced the expansion of their collaboration granting Genocea the right to use Isconova's Matrix M in vaccines targeting two additional diseases.

23 Aug 2011

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Pfizer Inc today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company's supplemental Biologics License Application (sBLA) for use of Prevnar 13, in adults aged 50 and older.

30 Jul 2011

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011

Streptococcus pneumoniae News and Research

Further Reading

New method can screen for bacterial genes that are expressed during meningitis

CLYD gene serves as crucial negative regulator in pulmonary fibrosis

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

New insight into causes of childhood pneumonia

Epidemic bacteria can damage mucins to enter and infect a body part

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Study investigates how bacteria change their disguise to evade vaccines

Pfizer’s Prevenar 13 gets US approval for adults

FDA approves Prevnar 13 pneumococcal conjugate vaccine for adults 50 and older

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

EC approves Pfizer's pneumococcal conjugate vaccine, Prevenar 13

Pfizer's Prevnar 13: Additional data from adult clinical studies presented at 49th IDSA

Furiex announces publications and presentations about antibacterial drug JNJ-Q2

Researchers discover how a novel type of antibody works against pneumococcal bacteria

High risk of serious complications or death in children with SP-HUS

Isconova expands Matrix M collaboration with Genocea to treat infectious diseases

FDA issues 90-day extension for Pfizer's Prevnar 13 sBLA to treat pneumonia in adults

Final Atlantis space trip may open new era of research into infectious diseases

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News